{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Somatostatin+Receptor+Positive+%28SSTR%2B%29&page=2",
    "query": {
      "condition": "Somatostatin Receptor Positive (SSTR+)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Somatostatin+Receptor+Positive+%28SSTR%2B%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T02:52:50.266Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04106843",
      "title": "Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Adrenal Gland Pheochromocytoma",
        "Locally Advanced Paraganglioma",
        "Metastatic Adrenal Gland Pheochromocytoma",
        "Metastatic Paraganglioma",
        "Metastatic Parathyroid Gland Carcinoma",
        "Pituitary Gland Carcinoma",
        "Somatostatin Receptor Positive",
        "Stage III Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8",
        "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8",
        "Unresectable Adrenal Gland Pheochromocytoma",
        "Unresectable Paraganglioma"
      ],
      "interventions": [
        {
          "name": "Lutetium Lu 177 Dotatate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-13",
      "completion_date": "2020-09-03",
      "has_results": false,
      "last_update_posted_date": "2020-09-07",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04106843"
    },
    {
      "nct_id": "NCT04081701",
      "title": "68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "CNS Tumors",
        "Meningioma",
        "Esthesioneuroblastoma",
        "Hemangioblastoma",
        "Medulloblastoma",
        "Paraganglioma",
        "Pituitary Adenoma"
      ],
      "interventions": [
        {
          "name": "Ga68-DOTATATE-PET/MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 200,
      "start_date": "2019-09-04",
      "completion_date": "2038-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04081701"
    },
    {
      "nct_id": "NCT01879657",
      "title": "68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "68Ga-DOTATATE",
          "type": "DRUG"
        },
        {
          "name": "PET/CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "111In-pentetreotide OctreoScan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Radio Isotope Therapy of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2013-03-01",
      "completion_date": "2017-12-05",
      "has_results": false,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01879657"
    },
    {
      "nct_id": "NCT06784752",
      "title": "Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Somatostatin Receptor Positive (SSTR+)",
        "Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)"
      ],
      "interventions": [
        {
          "name": "[177Lu]Lu-DOTA-TATE",
          "type": "RADIATION"
        },
        {
          "name": "Octreotide LAR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 240,
      "start_date": "2025-05-30",
      "completion_date": "2034-01-23",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06784752"
    },
    {
      "nct_id": "NCT04919226",
      "title": "Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT",
          "type": "DRUG"
        },
        {
          "name": "CAPTEM (Capecitabine and Temozolomide)",
          "type": "DRUG"
        },
        {
          "name": "Amino-Acid Solution",
          "type": "OTHER"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "ITM Solucin GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2021-12-21",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 14,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Tampa, Florida + 10 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04919226"
    },
    {
      "nct_id": "NCT02359500",
      "title": "68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Carcinoid Tumors"
      ],
      "interventions": [
        {
          "name": "68Ga-DOTATOC PET",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lale Kostakoglu",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2014-12",
      "completion_date": "2017-01-23",
      "has_results": false,
      "last_update_posted_date": "2017-05-03",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02359500"
    },
    {
      "nct_id": "NCT03273712",
      "title": "Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Tumors",
        "Meningioma",
        "Neuroblastoma",
        "Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "90Y-DOTA tyr3-Octreotide",
          "type": "RADIATION"
        },
        {
          "name": "68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Amino Acids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DIAGNOSTIC_TEST",
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "6 Months to 90 Years"
      },
      "enrollment_count": 39,
      "start_date": "2017-09-29",
      "completion_date": "2020-05-27",
      "has_results": true,
      "last_update_posted_date": "2023-02-09",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03273712"
    },
    {
      "nct_id": "NCT05249114",
      "title": "Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Lu-177",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2022-12-28",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05249114"
    },
    {
      "nct_id": "NCT03673943",
      "title": "Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "64Cu-DOTATATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Radiomedix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2018-08-23",
      "completion_date": "2019-08-07",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03673943"
    },
    {
      "nct_id": "NCT07129252",
      "title": "A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "SST2-positive Neuroendocrine Neoplasms",
        "Neuroendocrine Tumors",
        "Neuroendocrine Neoplasm"
      ],
      "interventions": [
        {
          "name": "CRN09682",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crinetics Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-11-26",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-11",
      "last_synced_at": "2026-06-26T02:52:50.266Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Duarte, California • Newport Beach, California + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07129252"
    }
  ]
}